Active surveillance inclusion criteria under scrutiny in magnetic resonance imaging-guided prostate biopsy: a multicenter cohort study
Kornienko K, Siegel F, Borkowetz A, Hoffmann MA, Drerup M, Lieb V, Bruendl J, Hoefner T, Cash H, Von Hardenberg J, Westhoff N (2021)
Publication Type: Journal article
Publication year: 2021
Journal
DOI: 10.1038/s41391-021-00478-2
Abstract
Background Although multiparametric magnetic resonance imaging (mpMRI) is recommended for primary risk stratification and follow-up in Active Surveillance (AS), it is not part of common AS inclusion criteria. The objective was to compare AS eligibility by systematic biopsy (SB) and combined MRI-targeted (MRI-TB) and SB within real-world data using current AS guidelines. Methods A retrospective multicenter study was conducted by a German prostate cancer (PCa) working group representing six tertiary referral centers and one outpatient practice. Men with PCa and at least one MRI-visible lesion according to Prostate Imaging Reporting and Data System (PI-RADS) v2 were included. Twenty different AS inclusion criteria of international guidelines were applied to calculate AS eligibility using either a SB or a combined MRI-TB and SB. Reasons for AS exclusion were assessed. Results Of 1941 patients with PCa, per guideline, 583-1112 patients with PCa in both MRI-TB and SB were available for analysis. Using SB, a median of 22.1% (range 6.4-72.4%) were eligible for AS. Using the combined approach, a median of 15% (range 1.7-68.3%) were eligible for AS. Addition of MRI-TB led to a 32.1% reduction of suitable patients. Besides Gleason Score upgrading, the maximum number of positive cores were the most frequent exclusion criterion. Variability in MRI and biopsy protocols potentially limit the results. Conclusions Only a moderate number of patients with PCa can be monitored by AS to defer active treatment using current guidelines for inclusion in a real-world setting. By an additional MRI-TB, this number is markedly reduced. These results underline the need for a contemporary adjustment of AS inclusion criteria.
Authors with CRIS profile
Involved external institutions
Ruprecht-Karls-Universität Heidelberg
Germany (DE)
Technische Universität Dresden
Germany (DE)
Paracelsus Medizinische Privatuniversität
Austria (AT)
Bundesministerium der Verteidigung / Bundeswehr
Germany (DE)
Johannes Gutenberg-Universität Mainz (JGU)
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Universität Regensburg
Germany (DE)
Germany (DE)
Technische Universität Dresden
Germany (DE)
Paracelsus Medizinische Privatuniversität
Austria (AT)
Bundesministerium der Verteidigung / Bundeswehr
Germany (DE)
Johannes Gutenberg-Universität Mainz (JGU)
Germany (DE)
Charité - Universitätsmedizin Berlin
Germany (DE)
Universität Regensburg
Germany (DE)
How to cite
APA:
Kornienko, K., Siegel, F., Borkowetz, A., Hoffmann, M.A., Drerup, M., Lieb, V.,... Westhoff, N. (2021). Active surveillance inclusion criteria under scrutiny in magnetic resonance imaging-guided prostate biopsy: a multicenter cohort study. Prostate Cancer and Prostatic Diseases. https://doi.org/10.1038/s41391-021-00478-2
MLA:
Kornienko, Kira, et al. "Active surveillance inclusion criteria under scrutiny in magnetic resonance imaging-guided prostate biopsy: a multicenter cohort study." Prostate Cancer and Prostatic Diseases (2021).
BibTeX: Download